<DOC>
	<DOCNO>NCT01253408</DOCNO>
	<brief_summary>Irritable bowel syndrome ( IBS ) affect 15 % U.S. population . There still effective safe medication approve treatment abdominal pain associate bowel symptom IBS . This study investigate effect approve medication , Dronabinol , movement food stomach colon subject history diarrhea-predominant Irritable Bowel Syndrome ( D-IBS ) . Dronabinol synthetic medication ( medication make laboratory ) relate active ingredient `` cannabinoid marijuana '' . Dronabinol approve Food Drug Administration ( FDA ) prevent nausea vomit patient cancer undergo chemotherapy . It also use AIDS patient excessive weight loss improvement appetite weight gain . The hypothesis study dronabinol slow movement food colon , effect regulate gene control body messenger ( receptor ) respond medicinal marijuana synthetic medicine work messenger present gastrointestinal tract pain nerve .</brief_summary>
	<brief_title>Effect Cannabinoid Agonist Gastrointestinal Colonic Motor Functions Patients With Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>Irritable bowel syndrome ( IBS ) affect 15 % U.S. population . Despite increase understanding pathophysiology IBS , unmet clinical need effective medication approve treatment abdominal pain associate IBS . Cannabinoid receptor ( CBR ) cholinergic neuron brain stem , stomach colon . A cannabinoid receptor type 1 ( CB1 ) antagonist , rimonabant , effective induction weight loss ; however , mechanism benefit unclear . Human study lab show CBR agonist , dronabinol , inhibit gastric colonic motility , may alter appetite satiation obesity , may potential treatment IBS . The overall focus study mechanism involve modulation gastric colonic motor sensory function cannabinoid receptor ( CBR ) health IBS . CB1 receptor also involved nociception mediate inflammation increasingly recognize potential pathophysiological mechanism IBS . The aim study compare effect two dos cannabinoid agonist , dronabinol ( 5 10 mg/day ) placebo gastrointestinal colonic motor sensory function IBS . Also , determine whether variation fatty acid amide hydrolase ( FAAH ) gene monoacylglycerol lipase ( MGLL ) gene ( rate limit enzyme , monoacylglycerol lipase , another endocannabinoid , 2-arachidonyl glycerol ) influence pharmacological effect cannabinoid modulation gastrointestinal motor sensory function . All participant undergo follow procedure : 1 . Documentation eligibility , screen questionnaire , physical examination within month prior study . The physical exam include standard rectal pelvic floor examination exclude rectal evacuation disorder . This necessary ensure diarrhea w secondary `` retention stool overflow . '' 2 . Baseline colonic transit measurement ( Geometric Center 24-h 48-h ) , treatment . 3 . Treatment day correspond scintigraphic transit test day ( day 1 2 ) participant receive medication randomize . Scintigraphic measurement gastric , small bowel , colonic transit conduct , use previously validate method day 1 2 , complete fast 48-h scan day 3 medication administer . On day 1 2 , morning dose medication ingest research laboratory , participant fasting . On day 1 , morning dose medication administer together delayed release capsule contain isotope label activated charcoal use measure colonic transit . On day 2 , morning dose medication give 24-h scan . The evening dose day 1 2 ingested participant bed time home . 4 . With appropriate consent , venous blood sample obtain participant DNA extraction pharmacogenomic study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Cannabinoid Receptor Agonists</mesh_term>
	<criteria>Age 1875 year Positive IBS symptoms Rome III criteria No prior abdominal surgery ( except appendectomy cholecystectomy ) Baseline Geometric Center 24 hour greater/equal 2.0 Baseline Geometric Center 48 hour greater/equal 3.9 Patients significant depression ( score great 10 Hospital Anxiety Inventory ) Patients anxiety ( score great 10 Hospital Anxiety Inventory ) allow participate . However , patient stable dos selective serotonin reuptake inhibitor ( SSRIs ) low dose tricyclic antidepressant eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>anandamide</keyword>
	<keyword>cannabinoid</keyword>
	<keyword>fatty acid amide hydrolase</keyword>
	<keyword>gastric</keyword>
	<keyword>motility</keyword>
	<keyword>small bowel</keyword>
</DOC>